Protalix Biotherapeutics (PLX) Trading Up 14%

Shares of Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) were up 14% during mid-day trading on Friday . The stock traded as high as $0.51 and last traded at $0.49. Approximately 1,049,643 shares were traded during trading, an increase of 58% from the average daily volume of 663,791 shares. The stock had previously closed at $0.43.

Several analysts recently issued reports on PLX shares. Zacks Investment Research lowered Protalix Biotherapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 9th. HC Wainwright set a $4.00 target price on Protalix Biotherapeutics and gave the stock a “buy” rating in a report on Thursday, December 13th.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PLX. Virtu Financial LLC raised its holdings in Protalix Biotherapeutics by 44.4% during the fourth quarter. Virtu Financial LLC now owns 91,862 shares of the company’s stock worth $29,000 after acquiring an additional 28,236 shares in the last quarter. Fosun International Ltd bought a new stake in Protalix Biotherapeutics during the third quarter worth about $1,881,000. Finally, Renaissance Technologies LLC raised its holdings in Protalix Biotherapeutics by 24.9% during the third quarter. Renaissance Technologies LLC now owns 3,266,401 shares of the company’s stock worth $2,374,000 after acquiring an additional 651,701 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: “Protalix Biotherapeutics (PLX) Trading Up 14%” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at https://sportsperspectives.com/2019/03/15/protalix-biotherapeutics-plx-trading-up-14.html.

Protalix Biotherapeutics Company Profile (NYSEAMERICAN:PLX)

Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease.

Recommended Story: What is dollar cost averaging (DCA)?

Receive News & Ratings for Protalix Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.